February 25, 2022
Translational Research Integration & Support Co-lead, Singapore Translational Cancer Consortium;
Principal Investigator and Facility Head (Microscopy), Cancer Science Institute of Singapore;
Consultant, Department of Haematology-Oncology, National University Cancer Institute Singapore;
Assistant Professor; Department of Medicine, Yong Loo Lin School of Medicine, NUS;
Assistant Director of Research (Medical Oncology), Department of Haematology-Oncology, National University Health System
Dr Jeyasekharan obtained his undergraduate medical degree from Christian Medical College Vellore, India in 2003. He then completed a PhD in Oncology (2008) under the mentorship of Professor Ashok Venkitaraman at the University of Cambridge UK, on a Gates Cambridge Scholarship. Following a post-doctoral fellowship in Cambridge as a Junior Research Fellow (Wolfson), he joined the National University Hospital Singapore in 2010 to complete his training in Internal Medicine, and Medical Oncology (2016). He has been active in medical research at the National University Health System, and holds a joint appointment at the Cancer Science Institute, where he has run a basic science laboratory since 2013.
Dr Jeyasekharan’s clinical interest is in aggressive B-cell neoplasms, and he is currently a consultant medical oncologist on the National University Hospital lymphoma team. He also serves as the assistant director of research for the division of medical oncology at National University Hospital, and is an active member of the NUHS clinician-scientist unit, where he administers the National University Hospital Clinician-Scientist Program for Residents (NCSP-R).
A new national consortium – the Consortium for Clinical Research and Innovation, Singapore (CRIS) – has been officially launched by the Minister for Health Mr Ong Ye Kung on 6 April 2022 CRIS brings together five key national R&D, clinical translation and service initiatives that will advance clinical research and innovation for Singapore, and establish important capabilities for a future-ready healthcare system
Delfi Diagnostics’ liquid biopsy test uses machine learning to spot changes in patients’ DNA fragmentation profiles that indicate the presence of cancerous cells.